Clinical Trial Update: An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell Lymphoma [EARLY_Phase 1]

View source ↗

Summary

An open, dose-escalation early Phase 1 study of CAR-T cells targeting CD19 and CD20 for relapsed or refractory aggressive B-cell lymphoma is currently recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• CD19/CD20 CAR-T cell therapy (CD19 and CD20 targeted chimeric antigen receptor T cells)

Snippet

Sponsor: Peking University People's Hospital | Conditions: R/R Aggressive B-cell Lymphoma | EARLY_Phase 1 | Status: RECRUITING